SSL continues to seek medical division buyer in 2004
This article was originally published in Clinica
Executive Summary
SSL International, the UK consumer and medical products group, says it is still in "the late stages of discussions" over a planned sale of its medical activities. However, it will not complete the divestment of the division, which is expected to be sold in two parts - comprising woundcare, and antiseptic gels and gloves - by the end of 2003, a deadline it had previously told Clinica it would meet (see Clinica No 1075, p 18).
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.